MALDI mass spectrometry Agilent Q3 Revenues Up 6 Percent The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter. Biodesix, MRM Proteomics Partner on Lung Cancer Assays Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer. Bruker Receives FDA Approval for Expanded MALDI Biotyper The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation. At ASMS 2017, Vendors Focus on Software, Applications Premium With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms. Bruker Daltonics, AMRI, HighRes Biosolutions Collaborate on Mass Spec for Drug Discovery The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center. Dec 2, 2016 TP53 Variants May Influence Cancer Risk in Taiwanese Lynch Syndrome Cohort May 11, 2016 Protea Tiptoes Towards Clinical Diagnostics With Mass Spec Imaging Melanoma Test Premium Apr 8, 2016 SimulTOF Looking to Apply its MALDI Instruments to Microbial ID Premium Feb 25, 2016 At MSACL 2016, Extra Attention on Mass Spec-Based Dx Nov 20, 2013 NCI Awards Labcyte $1M to Develop Mass Spec-based Cancer Biomarker Detection Method Aug 2, 2013 New Study Further Bolsters Case for Bruker's MALDI Biotyper as Broad Clinical Proteomics Platform Premium Jun 20, 2013 Bruker Signs Deal with ImaBiotech to Distribute Quantinetix Software for MALDI MS Imaging Jun 5, 2013 Bruker, CovalX Combine Technologies for MALDI MS-based Research Jun 4, 2013 Bruker Inks Patent License Deal with 3M for Technology Related to MALDI Imaging of FFPE Tissue May 14, 2013 Bruker Enters Partnership with Scils for MALDI Imaging Software Apr 29, 2013 BD, Bruker Update Collaboration on Antimicrobial Technologies Apr 19, 2013 Bruker, GBC Proteomics Centre Protein Assay Deal Points to New Clinical Markets for MALDI Biotyper Premium Apr 18, 2013 Bruker, Genome BC Proteomics Centre Team on Development of MALDI-MS Assays Apr 2, 2012 Bruker, UMCG Collaborating on Anaerobic Bacteria Identification Using MALDI Biotyper Dec 6, 2011 Ezose Sciences Integrated into Shionogi Diagnostic Business Nov 8, 2011 NCI Awards Labcyte $196K to Develop Cancer Biomarker Validation System Jul 22, 2011 Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec Premium May 20, 2011 Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs Premium Apr 8, 2011 Vanderbilt Wins $10M from NCRR to Establish Proteomics Imaging Resource Premium Apr 8, 2011 Bruker Gets Health Canada Approval for IVD MALDI Biotyper, Closes Michrom Acquisition Premium Load More Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.